Saif Muhammad Wasif
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.
Onco Targets Ther. 2009 Feb 18;2:29-41. doi: 10.2147/ott.s3469.
Capecitabine is currently the only novel, orally home-administered fluorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors, including breast cancer, colorectal cancer, gastric cancer, and many others. Furthermore, the drug compares favorably with fluorouracil in patients with such cancers, with a safe toxicity profile, consisting mainly of gastrointestinal and dermatologic adverse effects. Whereas gastrointestinal events and hand-foot syndrome occur often with capecitabine, the tolerability profile is comparatively favorable. Prompt recognition of severe adverse effects is the key to successful management of capecitabine. Ongoing and future clinical trials will continue to examine, and likely expand, the role of capecitabine as a single agent and/or in combination with other anticancer agents for the treatment of gastrointestinal as well as other solid tumors, both in the advanced palliative and adjuvant settings. The author summarizes the current data on the role of capecitabine in the management of gastrointestinal cancers.
卡培他滨是目前唯一一种新型的、可在家口服的氟尿嘧啶前体药物。它使患者减少了去医院就诊的次数，减少了与输液装置相关的不便和并发症。该药物已在包括乳腺癌、结直肠癌、胃癌等多种实体瘤的大型临床试验中得到广泛研究。此外，在患有此类癌症的患者中，该药物与氟尿嘧啶相比具有优势，其毒性特征安全，主要包括胃肠道和皮肤不良反应。虽然卡培他滨常出现胃肠道事件和手足综合征，但其耐受性相对较好。及时识别严重不良反应是成功管理卡培他滨的关键。正在进行和未来的临床试验将继续研究，并可能扩大卡培他滨作为单一药物和/或与其他抗癌药物联合用于治疗晚期姑息和辅助治疗环境中的胃肠道以及其他实体瘤的作用。作者总结了卡培他滨在胃肠道癌症管理中的当前数据。
